Limbic is a technology company.
Limbic helps behavioral health organizations scale access, speed up care, and improve outcomes without increasing staff or sacrificing quality. This is clinical AI with no compromise.
Limbic has raised $14.0M across 1 funding round.
Limbic has raised $14.0M in total across 1 funding round.
Limbic has raised $14.0M in total across 1 funding round.
Limbic's investors include Gaingels, Khosla Ventures, Synergis Capital, Furqan Rydhan, Hubert Thieblot.
Limbic is a clinical artificial intelligence company specializing in mental healthcare technology. It develops AI-powered tools such as Limbic Access, an AI clinical assistant that automates patient intake and assessments, and Limbic Care, a generative AI companion providing on-demand patient support. These products help mental health providers scale access, accelerate care delivery, and improve patient outcomes without increasing staff or compromising quality. Limbic’s AI technology is clinically validated and compliant with healthcare regulations, addressing workforce shortages and administrative burdens in mental health services[1][3][5].
Limbic was founded by experts in neuroscience, artificial intelligence, psychiatry, and digital health, including CEO Dr. Ross Harper, a neuroscientist and entrepreneur, and CTO Sebastiaan de Vries, an experienced tech founder. The team’s background spans prestigious institutions like Cambridge, UCL, and Stanford. The company began in the UK and was the first AI chatbot to earn Class IIa medical device status, a regulatory certification for safety and efficacy in healthcare software. Early adoption in the UK’s NHS talk therapy services and clinical validation helped Limbic expand into the US market, where its evidence-based AI tools have gained traction among behavioral health providers[1][3][5].
Limbic rides the growing trend of applying AI and generative language models to healthcare, particularly mental health, where demand far exceeds provider capacity. The timing is critical as mental health services face workforce shortages and increasing patient loads globally. Limbic’s clinically validated AI tools help expand access to care, reduce wait times, and improve treatment adherence, aligning with broader healthcare digitization and AI adoption trends. Its regulatory certifications and clinical evidence set a high standard for safe AI integration in healthcare, influencing how AI can be responsibly deployed in sensitive clinical environments[1][3][5].
Limbic is positioned to expand its impact by broadening language support and scaling adoption across more healthcare systems, especially in the US. Future trends shaping its journey include advances in generative AI, increasing regulatory scrutiny, and growing demand for scalable mental health solutions. As AI becomes more embedded in clinical workflows, Limbic’s focus on safety, compliance, and clinical validation will likely strengthen its leadership role. Its influence may grow beyond mental health into other healthcare domains requiring trustworthy AI assistance, continuing to transform how care is delivered at scale[1][3][5].
Limbic has raised $14.0M across 1 funding round. Most recently, it raised $14.0M Series A in March 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Mar 1, 2024 | $14.0M Series A | Gaingels, Khosla Ventures, Synergis Capital, Furqan Rydhan, Hubert Thieblot |